Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Peking University First Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled. HBsAg/anti-HBs level, HBeAg/anti-HBe level, Serum HBV DNA load and alanine transaminase level will be test every year from the second year to the fifth year after the ending of peginterferon alfa treatment, and long-term benefit of interferon treatment will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| peginterferon alfa 2b |
| ||
| peginterferon alfa 2a |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Peginterferon Alfa-2B | Drug | pre-received standard peginterferon alfa-2b therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| rate of HBeAg seroconversion | from the second year to the fifth year |
| Measure | Description | Time Frame |
|---|---|---|
| decent degree of HBeAg | from the second year to the fifth year | |
| decent degree of HBV DNA | from the second year to the fifth year | |
| rate of alanine aminotransferase normalization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with chronic hepatitis B who previously participated in TB1211IFN study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Guiqiang Wang, MD | Peking University First Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 302 Military Hospital | Beijing | Beijing Municipality | China | |||
| Beijing Ditan Hospital Capital Medical University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
plasma, hemocyte
| Peginterferon Alfa-2A | Drug | pre-received standard peginterferon alfa-2a therapy |
|
|
| from the second year to the fifth year |
| rate of HBeAg loss | from the second year to the fifth year |
| rate of HBV DNA undetectable | from the second year to the fifth year |
| rate of HBeAg seroconversion | from the second year to the fifth year |
| Beijing |
| Beijing Municipality |
| China |
| Beijing Youan Hospital, Capital Medical University | Beijing | Beijing Municipality | China |
| Peking University First Hospital | Beijing | Beijing Municipality | China |
| Peking University People's Hospital | Beijing | Beijing Municipality | China |
| Second Affiliated Hospital Chongqing Medical University | Chongqing | Chongqing Municipality | China |
| Southwest Hospital | Chongqing | Chongqing Municipality | China |
| Fuzhou Infectious Disease Hospital | Fuzhou | Fujian | China |
| The First Affiliated Hospital of Xiamen University | Xiamen | Fujian | China |
| Xiamen Hospital of T.C.M | Xiamen | Fujian | China |
| Guangzhou Eighth People's Hospital | Guangzhou | Guangdong | China |
| Nanfang Hospital | Guangzhou | Guangdong | China |
| Beijing University Shenzhen Hospital | Shenzhen | Guangdong | China |
| Third Affiliated Hospital, Hebei Medical University | Shijiazhuang | Hebei | China |
| Henan Provincial People's Hospital | Zhengzhou | Henan | China |
| Xiangya Hospital, Central-south University | Changsha | Hunan | China |
| Xiangya Second Hospital, Central-south University | Changsha | Hunan | China |
| 81 Military Hospital | Nanjing | Jiangsu | China |
| Second Hospital of Nanjing | Nanjing | Jiangsu | China |
| First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi | China |
| Shenyang Sixth People's Hospital | Shenyang | Liaoning | China |
| Jinan Infectious Disease Hospital | Jinan | Shandong | China |
| 85 Military Hospital | Shanghai | Shanghai Municipality | China |
| Huashan Hospital | Shanghai | Shanghai Municipality | China |
| Ruijing Hospital | Shanghai | Shanghai Municipality | China |
| Shanghai Public Health Clinical Center | Shanghai | Shanghai Municipality | China |
| Tianjin Third Central Hospital | Tianjin | Tianjin Municipality | China |
| First Affiliated Hospital of Wenzhou Medical College | Wenzhou | Zhejiang | China |
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C417083 | peginterferon alfa-2b |
| C100416 | peginterferon alfa-2a |
Not provided
Not provided
Not provided